Dr. Xiaosheng Wang, associate professor at China Pharmaceutical University, doctoral supervisor, and member of the expert committee of the Rehabilitation Medicine Research Center of Zhejiang University School of Medicine. PhD in Bioinformatics from Kyoto University, Japan. Postdoctoral fellow at the National Institutes of Health (NIH) and lecturer at the University of Nebraska Medical Center (UNMC). His main research interests include: bioinformatics, medical genomics, tumor immunotherapy, systems biology, and biostatistics.

As a major contributor, he has published more than 100 SCI papers in high-profile journals, such as Journal of Medical Virology (IF=20.693, independent corresponding author), Briefings in Bioinformatics (IF=13.994, independent communication), Journal of Experimental & Clinical Cancer Research (IF=12.658, independent communication), Journal for ImmunoTherapy of Cancer (IF=12.469, independent communication), EBioMedicine (IF=11.205, independent communication), Science of The Total Environment (IF=10.753, independent communication), Infectious Diseases of Poverty (IF=10.485, independent communication), npj Precision Oncology (IF=10.092, independent communication), Journal of Neuroinflammation (IF=9.587, independent communication), Frontiers in Immunology (IF=8.786, independent or first communication), Clinical and Translational Medicine (IF=8.554, independent communication), Journal of Translational Medicine (IF=8.440, independent or first communication), Computers in Biology and Medicine (IF=7.7, independent communication), Cellular Oncology (IF=7.051, independent communication), Communications Biology (IF=6.548, independent communication), Computational and Structural Biotechnology Journal (IF=6.155, Independent or First Communications), and obtained 2 software patents.

Currently he is an associate editor or editorial board member of several journals, including Heliyon, Scientific Reports, Frontiers in Genetics, the World Journal of Gastrointestinal Oncology, and Journal of Clinical Medicine, and reviewers for numerous journals, such as The Lancet Respiratory Medicine, Journal of the National Cancer Institute, Nucleic Acids Research, Journal for ImmunoTherapy of Cancer, EBioMedicine, npj Precision Oncology, and MED, and reviewers for research fundings from The European Research Council (ERC) Consolidator Fund, Swiss National Science Foundation (SNSF) Fund, and The Israel Science Foundation (ISF) Fund.

Influential academic achievements in recent years include:

1. Due to his research on tumor immune genome, he was invited to give a special report at the international branch of The 78th Annual Meeting of the Japanese Cancer Association held in Japan in September 2019.

2. Discovered markers related to tumor immunity and tumor immunotherapy response, including gene (TP53, ARID1A, KALRN, PLK1, HRAS and HIF1A) and pathway (cell cycle, glycolysis, neurotrophin, spliceosome) markers, for which have published More than 10 related papers.

3. Developed algorithms DEPTH and DEPTH2 to define intratumor heterogeneity based on the asynchrony of tumor cell transcriptome changes, and proved that the algorithms are significantly superior to other algorithms in assessing tumor heterogeneity.

4. Proposed an unsupervised machine learning method based on immune gene set scoring to perform immunological classification of tumors. This method can be used to identify tumor subtypes suitable for immunotherapy and has been adopted by many researchers. Related papers have been published in Google Scholar has been cited more than 350 times.

5. The first to systematically study the association between p53 mutations and tumor immunity in various tumor types, and found that p53 mutations enhance tumor immunity in some tumor types but inhibit tumor immunity in other tumor types. It was revealed that the main reason for this difference is that the impact of p53 mutation on genome instability is different in these tumor types. Four related papers have been published.

6. Developed the “Cancer Omics Atlas Database” database, which is widely used by academic circles at home and abroad. The link to the database is: https://tcoa.cpu.edu.cn/, and the database has been accessed more than 434,000 times.

7. The first systematic analysis of the expression of the SARS-CoV-2 new coronavirus receptor gene ACE2 in various human normal tissues and organs, virus-infected tissues and tumor tissues, providing the theoretical basis for the new coronavirus to infect various human tissues and organs besides the lungs; first to reveal that ACE2 is a potential protective factor that prevents tumor progression and that ACE2 can promote tumor immunotherapy response. Three related papers have been published, with more than 2,000 Google citations.

Representative papers in recent years (*corresponding author):

1. Qiushi Feng, Zehua Dong, Rongfang Nie, Xiaosheng Wang^*, Identifying Diffuse Glioma Subtypes Based on Pathway Enrichment, Interdisciplinary Sciences: Computational Life Sciences, 2024, DOI: 10.1007/s12539-024-00627-w.

2. Zijie Wu, Zehua Dong, Jiangti Luo, Weiwei Hu, Yue Tong, Xiangdong Gao, Wenbing Yao^*, Hong Tian^*, Xiaosheng Wang^*, A comprehensive comparison of molecular and phenotypic profiles between hepatitis B virus (HBV)-infected and non-HBV-infected hepatocellular carcinoma by multi-omics analysis, Genomics, 2024, 116: 110831.

3. Zeinab Abdelrahman^*, Alaa Abdelatty, Jiangti Luo, Amy Jayne McKnight, Xiaosheng Wang^*, Stratification of glioma based on stemness scores in bulk and single-cell transcriptomes, Computers in Biology and Medicine, 2024, 175: 108304.

4. Yuehong Luo, Ting Li, Rongzhuo Long, Qinglong Guo, Libin Wei^*, Xiaosheng Wang^*, Exploring targets and related mechanisms of Scutellaria baicalensis for treating non-small cell lung cancer based on network pharmacology, Pharmacological Research - Modern Chinese Medicine, 2024, 10: 100381.

5. Yin He, Xiaosheng Wang^*, Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis, Computers in Biology and Medicine, 2023, 167: 107591.

6. Jiali Lei, Jiangti Luo, Qian Liu, Xiaosheng Wang^*, Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer, Cellular Oncology, 2023, https://doi.org/10.1007/s13402-023-00886-7.

7. Tao Yang, Qiyu Yan, Rongzhuo Long, Zhixian Liu^*, Xiaosheng Wang^*, PreCanCell: An Ensemble Learning Algorithm for Predicting Cancer and Non-Cancer Cells from Single-Cell Transcriptomes, Computational and Structural Biotechnology Journal, 2023, 21: 3604-3614.

8. Hongjing Ai, Dandan Song, Xiaosheng Wang^*, Defining multiple layers of intratumor heterogeneity based on variations of perturbations in multi-omics profiling, Computers in Biology and Medicine, 2023, 159: 106964.

9. Zehua Dong, Qiyu Yan, Wenxiu Cao, Zhixian Liu, Xiaosheng Wang^*, Identification of key molecules in COVID-19 patients significantly correlated with clinical outcomes by analyzing transcriptomic data, Frontiers in Immunology, 2022, 13: 930866.  

10. Rongfang Nie, Zeinab Abdelrahman, Zhixian Liu, Xiaosheng Wang^*, Evaluation of the role of vaccination in the COVID-19 pandemic based on the data from the 50 U.S. States, Computational and Structural Biotechnology Journal, 2022, 20: 4138-4145.

11. Hongjing Ai, Rongfang Nie, Xiaosheng Wang^*, Evaluation of the effects of meteorological factors on COVID-19 prevalence by the distributed lag nonlinear model, Journal of Translational Medicine, 2022, 20: 170.

12. Dandan Song, Xiaosheng Wang^*, DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls, Journal of Translational Medicine, 2022, 20: 150.

13. Qian Liu, Jiali Lei, Xiaobo Zhang, Xiaosheng Wang^*, Classification of Lung Adenocarcinoma Based on Stemness Scores in Bulk and Single Cell Transcriptomes, Computational and Structural Biotechnology Journal, 2022, 20: 1691-1701.

14. Xiaojun Zhu, Shengwei Li, Jiangti Luo, Xia Ying, Zhu Li, Yuanhe Wang, Mengmeng Zhang, Tianfang Zhang, Peiyue Jiang, Xiaosheng Wang^*, Subtyping of human papillomavirus-positive cervical cancers based on the expression profiles of 50 genes, Frontiers in Immunology, 2022, 13: 801639.

15. Jiali Lei, Mengyuan Li, Xiaosheng Wang^*, Predicting the development trend of the second wave of COVID-19 in five European countries, Journal of Medical Virology, 2021, 93: 5896-5907.

16. Zeinab Abdelrahman, Qian Liu, Shanmei Jiang, Mengyuan Li, Yue Zhang, Xiaosheng Wang^*, Evaluation of the current therapeutic approaches for COVID-19: a systematic review and a meta-analysis,Frontiers in Pharmacology, 2021, 12, 607408.

17. Lin Li, Canping Chen, Xiaosheng Wang^*, DITHER: an algorithm for Defining IntraTumor Heterogeneity based on EntRopy, Briefings in Bioinformatics, 2021, 22(6): 1-13.

18. Lin Li, Xiaosheng Wang^*, Identification of gastric cancer subtypes based on pathway clustering, npj Precision Oncology, 2021, 5: 46.

19. Zeinab Abdelrahman, Zuobing Chen, Haoyu Lyu, Xiaosheng Wang^*, Comparisons of the immunological landscape between COVID-19, influenza, and respiratory syncytial virus patients by clustering analysis, Computational and Structural Biotechnology Journal, 2021, 19: 2347-2355.

20. Mengyuan Li, Xiaonan Guo, Xiaosheng Wang^*, Retrospective prediction of the epidemic trend of COVID-19 in Wuhan at four phases, Journal of Medical Virology, 2021, 93: 2493–2498.

21. Qiushi Feng, Lin Li, Mengyuan Li, Xiaosheng Wang^*, Immunological Classification of Gliomas Based on Immunogenomic Profiling Journal of Neuroinflammation, Journal of Neuroinflammation, 2020, 17: 360.

22. Mengyuan Li, Yuxiang Ma, You Zhong, Qian Liu, Canping Chen, Lei Qiang, Xiaosheng Wang^*, KALRN mutations promote antitumor immunity and immunotherapy response in cancer, Journal for ImmunoTherapy of Cancer, 2020, 8: e000293.

23. Shanmei Jiang, Yin He, Mengyuan Li, Xiaosheng Wang^*, Cell cycle activity correlates with increased anti-tumor immunity in diverse cancers, Clinical and Translational Medicine, 2020, 10(2): e98.

24. Mengyuan Li, Zhilan Zhang, Wenxiu Cao, Yijing Liu, Beibei Du, Canping Chen, Qian Liu, Md. Nazim Uddin, Shanmei Jiang, Cai Chen, Yue Zhang, Xiaosheng Wang^*, Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach, Science of The Total Environment, 2020, 764: 142810.

25. Zhilan Zhang, Lin Li, Mengyuan Li, Xiaosheng Wang^*, The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression, Computational and Structural Biotechnology Journal, 2020, 18: 2438-2444.

26. Lin Li, Qiushi Feng, Xiaosheng Wang^*, PreMSIm: an R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer, Computational and Structural Biotechnology Journal, 2020, 18: 668-675.

27. Zeinab Abdelrahman, Mengyuan Li, Xiaosheng Wang^*, Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses, Frontiers in Immunology, 2020, 11: 552909.

28. Baotao Chen, Lin Li, Mengyuan Li, Xiaosheng Wang^*, HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers, Cellular Oncology, 2020, 43(5):877-888.

29. Yunyao Liu, Xiaoping Wang, Wenshu Li, Yujiao Xu, Yating Zhuo, Mengyuan, Yuan He, Xiaosheng Wang, Qinglong Guo, Li Zhao^*, Lei Qiang^*, Oroxylin A reverses hypoxia-induced cisplatin resistance through 3 inhibiting HIF-1α mediated XPC transcription, Oncogene, 2020, 39: 6893-6905.

30. Mengyuan Li, Zhilan Zhang, Lin Li, Xiaosheng Wang^*, An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles, Communications Biology, 2020, 3: 505.

31. Meng-Yuan Li, Lin Li, Yue Zhang, Xiao-Sheng Wang^*, Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues, Infectious Diseases of Poverty, 2020, 9: 45.

32. Wenxiu Cao, Canping Chen, Mengyuan Li, Rongfang Nie, Qiqi Lu, Dandan Song,Shengwei Li, Tao Yang, Yijing Liu, Beibei Du, Xiaosheng Wang^*, Important factors affecting COVID-19 transmission and fatality in metropolises, Public Health, 2020, 190: e21-e23.

33. Lin Li, Mengyuan Li, Xiaosheng Wang^*, Cancer type-dependent correlations between TP53 mutations and antitumor immunity, DNA Repair, 2020, 88: 102785.

34. Zehang Jiang, Zhixian Liu, Mengyuan Li, Cai Chen, Xiaosheng Wang^*, Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment, EBioMedicine, 2019, 42(2019): 431-442.

35. Haoyu Lyu, Mengyuan Li, Zehang Jiang, Zhixian Liu, Xiaosheng Wang^*, Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer, Computational and Structural Biotechnology Journal, 2019, 17: 1020-1030.

36. Rong Fu, Chen-Feng Han, Ting Ni, Xiao-Sheng Wang, Zhao-Qiu Wu^*. A ZEB1/p53 signaling axis in stromal fibroblasts promotes mammary epithelial tumours, Nature Communications, 2019, 10(1): 3210.

37. Xiaosheng Wang^*, Mengyuan Li, Correlate tumor mutation burden with immune signatures in human cancers, BMC Immunology, 2019, 20: 4.

38. Yin He, Zehang Jiang, Cai Chen, Xiaosheng Wang^*, Classification of triple-negative breast cancers based on Immunogenomic profiling, Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 327.